Journal Article

Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction

Pierce, Gregory, Inculet, Richard I, Palma, David A, Erickson, Abigail L, Rodrigues, George B, Dar, A Rashid, Yu, Edward, Yaremko, Brian P, Malthaner, Richard A

2013

Overview

Purpose Multimodality therapy leads to improved outcomes for adenocarcinoma of the distal esophagus and gastroesophageal junction (GEJ) over surgery alone. At our institution, adjuvant chemoradiation (chemoRT) using IMRT and SIB is standard of care for resected high-risk disease. In this study, we review our experience with a recent cohort of patients treated in this manner. Methods and materials We identified 18 patients with resected T3 and/or N1 adenocarcinoma of the distal esophagus and GEJ who received adjuvant chemoRT. A large elective volume (PTV1) and a smaller high-risk volume (PTV2) were irradiated simultaneously using IMRT and an SIB technique. All patients received concurrent chemotherapy. Relevant clinical outcomes are reported. Results The median dose to 95% of PTV1 was 3747cGy and to 95% of PTV2 was 4876cGy. All RT was given in a median of 28 daily fractions. Four patients did not complete chemotherapy. At a median follow up of 952 days from the start of RT, 7 of 18 patients were dead; of these, 3 had developed local recurrence only; 3 had developed both local and distant recurrence; 1 died of a late toxicity, without recurrence. OS was 88% at 1year, 76% at 2 years and 58% at 3 years. Freedom from local recurrence was 88% at 1 year, 82% at 2 years and 82% at 3 years. Freedom from distant recurrence was 72% at 1 year, 67% at 2 years and 56% at 3 years. Toxicity was acceptable. Conclusions Adjuvant concurrent chemoRT with IMRT and SIB is feasible for resected high-risk adenocarcinoma of the distal esophagus and GEJ. Our results describe how modern treatment techniques can be employed as part of a treatment paradigm that is neither commonly used nor commonly described in the literature.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V
• Subject: Abdomen / Adenocarcinoma / Adenocarcinoma - mortality / Adenocarcinoma - pathology / Adenocarcinoma - therapy / Adjuvant treatment / Aged / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Biomedical and Life Sciences / Biomedicine / Cancer / Cancer Research / Cancer therapies / Care and treatment / Chemoradiotherapy / Chemotherapy / Chemotherapy, Adjuvant / Cisplatin - administration & dosage / Epirubicin - administration & dosage / Esophageal cancer / Esophageal Neoplasms - mortality / Esophageal Neoplasms - pathology / Esophageal Neoplasms - therapy / Esophagogastric Junction - pathology / Ethics / Female / Fluorouracil - administration & dosage / Follow-Up Studies / Health aspects / Health sciences / Humans / Imaging / Male / Medical research / Medicine, Experimental / Middle Aged / Neoplasm Recurrence, Local - mortality / Neoplasm Recurrence, Local - pathology / Neoplasm Recurrence, Local - therapy / Neoplasm Staging / Oncology / Organs at Risk - radiation effects / Ostomy / Prognosis / Radiation therapy / Radiology / Radiotherapy / Radiotherapy Planning, Computer-Assisted / Radiotherapy, Adjuvant / Radiotherapy, Conformal / Radiotherapy, Intensity-Modulated / Retrospective Studies / Reviews / Surgery / Survival analysis / Survival Rate / Toxicity